ZVSA
ZyVersa Therapeutics, Inc.
Biotechnology
Market Cap$1.19B
5Y Perf.-100.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ZVSA vs IMVT vs PRAX vs VKTX
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.89B
5Y Perf.+419.0%
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$9.98B
5Y Perf.+75.8%
VKTX
Viking Therapeutics, Inc.
Biotechnology
Market Cap$3.67B
5Y Perf.+846.6%
ZVSA vs IMVT vs PRAX vs VKTX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ZVSA | IMVT | PRAX | VKTX |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $1.19B | $5.89B | $9.98B | $3.67B |
| Revenue (TTM) | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income (TTM) | $-25M | $-464M | $-327M | $-472M |
| Total Debt | $0.00 | $98K | $110K | $137K |
| Cash & Equiv. | $102M | $714M | $357M | $166M |
ZVSA vs IMVT vs PRAX vs VKTX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ZVSA
IMVT
PRAX
VKTX
| Stock | Feb 22 | May 26 | Return |
|---|---|---|---|
| ZyVersa Therapeutic… (ZVSA) | 100 | 0.0 | -100.0% |
| Immunovant, Inc. (IMVT) | 100 | 519.0 | +419.0% |
| Praxis Precision Me… (PRAX) | 100 | 175.8 | +75.8% |
| Viking Therapeutics… (VKTX) | 100 | 946.6 | +846.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ZVSA vs IMVT vs PRAX vs VKTX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ZVSA leads in 2 of 6 categories, making it the strongest pick for capital preservation and lower volatility and operational efficiency and capital deployment. Immunovant, Inc. is the stronger pick specifically for growth and revenue expansion. PRAX and VKTX also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
ZVSA
ZyVersa Therapeutics, Inc.
The Income Pick
ZVSA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.61
- Rev growth -100.0%, EPS growth 50.7%
- Beta 0.61 vs VKTX's 1.54
- -25.6% ROA vs VKTX's -65.3%
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Defensive Pick
IMVT is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 1.36, Low D/E 0.0%, current ratio 11.16x
- Beta 1.36, current ratio 11.16x
- -21.3% revenue growth vs VKTX's -270.1%
Best for: sleep-well-at-night and defensive
PRAX
Praxis Precision Medicines, Inc.
The Momentum Pick
PRAX is the clearest fit if your priority is momentum.
- +8.3% vs ZVSA's -60.3%
Best for: momentum
VKTX
Viking Therapeutics, Inc.
The Long-Run Compounder
VKTX is the clearest fit if your priority is long-term compounding.
- 25.4% 10Y total return vs IMVT's 191.1%
- 4.7% margin vs ZVSA's -0.1%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMVT | -21.3% revenue growth vs VKTX's -270.1% |
| Quality / Margins | VKTX | 4.7% margin vs ZVSA's -0.1% |
| Stability / Safety | ZVSA | Beta 0.61 vs VKTX's 1.54 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PRAX | +8.3% vs ZVSA's -60.3% |
| Efficiency (ROA) | ZVSA | -25.6% ROA vs VKTX's -65.3% |
ZVSA vs IMVT vs PRAX vs VKTX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2024
Segment breakdown not available.
ZVSA vs IMVT vs PRAX vs VKTX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRAXLAGGINGVKTX
Who Leads Where
PRAX leads in 2 of 6 categories
ZVSA leads 1 • IMVT leads 0 • VKTX leads 0 • 2 tied
Explore the data ↓VKTXViking Therapeutics, …
0leads
IMVTImmunovant, Inc.
0leads
ZVSAZyVersa Therapeutics,…
1leads
PRAXPraxis Precision Medi…
2leads
6 Total Categories
CATEGORYLEADERvs ZVSAvs IMVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ZVSA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRAX4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ZVSA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ZVSA and VKTX operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | ZVSAZyVersa Therapeut… | IMVTImmunovant, Inc. | PRAXPraxis Precision … | VKTXViking Therapeuti… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $0 | $0 |
| EBITDAEarnings before interest/tax | -$25M | -$487M | -$357M | -$502M |
| Net IncomeAfter-tax profit | -$25M | -$464M | -$327M | -$472M |
| Free Cash FlowCash after capex | -$5.1B | -$423M | -$283M | -$340M |
| Gross MarginGross profit ÷ Revenue | — | — | — | — |
| Operating MarginEBIT ÷ Revenue | — | — | — | — |
| Net MarginNet income ÷ Revenue | — | — | — | — |
| FCF MarginFCF ÷ Revenue | — | — | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +93.6% | +19.7% | +2.7% | -2.3% |
ZVSA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — PRAX and VKTX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ZVSAZyVersa Therapeut… | IMVTImmunovant, Inc. | PRAXPraxis Precision … | VKTXViking Therapeuti… |
|---|---|---|---|---|
| Market CapShares × price | $1.2B | $5.9B | $10.0B | $3.7B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $5.2B | $9.6B | $3.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.05x | -10.61x | -25.63x | -9.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | — | — |
| Price / BookPrice ÷ Book value/share | — | 6.20x | 8.85x | 5.59x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Evenly matched — PRAX and VKTX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PRAX leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
PRAX delivers a -43.0% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-71 for VKTX. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to VKTX's 0.00x. On the Piotroski fundamental quality scale (0–9), PRAX scores 3/9 vs VKTX's 2/9, reflecting mixed financial health.
| Metric | ZVSAZyVersa Therapeut… | IMVTImmunovant, Inc. | PRAXPraxis Precision … | VKTXViking Therapeuti… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -47.1% | -43.0% | -71.3% |
| ROA (TTM)Return on assets | -25.6% | -44.1% | -40.2% | -65.3% |
| ROICReturn on invested capital | — | — | -65.0% | -44.4% |
| ROCEReturn on capital employed | — | -66.1% | -49.3% | -51.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 | 3 | 2 |
| Debt / EquityFinancial leverage | — | 0.00x | 0.00x | 0.00x |
| Net DebtTotal debt minus cash | -$102M | -$714M | -$357M | -$166M |
| Cash & Equiv.Liquid assets | $102M | $714M | $357M | $166M |
| Total DebtShort + long-term debt | $0 | $98,000 | $110,000 | $137,000 |
| Interest CoverageEBIT ÷ Interest expense | -49.28x | — | — | -15687.44x |
PRAX leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VKTX five years ago would be worth $51,394 today (with dividends reinvested), compared to $1 for ZVSA. Over the past 12 months, PRAX leads with a +831.3% total return vs ZVSA's -60.3%. The 3-year compound annual growth rate (CAGR) favors PRAX at 177.3% vs ZVSA's -89.0% — a key indicator of consistent wealth creation.
| Metric | ZVSAZyVersa Therapeut… | IMVTImmunovant, Inc. | PRAXPraxis Precision … | VKTXViking Therapeuti… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +48.0% | +11.8% | +20.6% | -10.5% |
| 1-Year ReturnPast 12 months | -60.3% | +110.2% | +831.3% | +19.3% |
| 3-Year ReturnCumulative with dividends | -99.9% | +57.3% | +2032.8% | +44.2% |
| 5-Year ReturnCumulative with dividends | -100.0% | +86.8% | +6.2% | +413.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | +191.1% | -17.1% | +2542.5% |
| CAGR (3Y)Annualised 3-year return | -89.0% | +16.3% | +177.3% | +13.0% |
PRAX leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ZVSA and PRAX each lead in 1 of 2 comparable metrics.
Risk & Volatility
ZVSA is the less volatile stock with a 0.61 beta — it tends to amplify market swings less than VKTX's 1.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 96.3% from its 52-week high vs ZVSA's 12.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ZVSAZyVersa Therapeut… | IMVTImmunovant, Inc. | PRAXPraxis Precision … | VKTXViking Therapeuti… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.61x | 1.36x | 1.40x | 1.54x |
| 52-Week HighHighest price in past year | $1.67 | $30.16 | $358.76 | $43.15 |
| 52-Week LowLowest price in past year | $0.11 | $13.52 | $35.21 | $22.96 |
| % of 52W HighCurrent price vs 52-week peak | +12.0% | +96.0% | +96.3% | +73.5% |
| RSI (14)Momentum oscillator 0–100 | 39.6 | 59.7 | 59.0 | 45.8 |
| Avg Volume (50D)Average daily shares traded | 8K | 1.4M | 377K | 2.3M |
Evenly matched — ZVSA and PRAX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: IMVT as "Buy", PRAX as "Buy", VKTX as "Buy". Consensus price targets imply 217.7% upside for VKTX (target: $101) vs 57.1% for IMVT (target: $46).
| Metric | ZVSAZyVersa Therapeut… | IMVTImmunovant, Inc. | PRAXPraxis Precision … | VKTXViking Therapeuti… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $45.50 | $548.80 | $100.75 |
| # AnalystsCovering analysts | — | 23 | 16 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRAX leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ZVSA leads in 1 (Income & Cash Flow). 2 tied.
Best OverallPraxis Precision Medicines,… (PRAX)Leads 2 of 6 categories
Loading custom metrics...
ZVSA vs IMVT vs PRAX vs VKTX: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is ZVSA or IMVT or PRAX or VKTX a better buy right now?
Analysts rate Immunovant, Inc.
(IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ZVSA or IMVT or PRAX or VKTX?
Over the past 5 years, Viking Therapeutics, Inc.
(VKTX) delivered a total return of +413. 9%, compared to -100. 0% for ZyVersa Therapeutics, Inc. (ZVSA). Over 10 years, the gap is even starker: VKTX returned +25. 4% versus ZVSA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ZVSA or IMVT or PRAX or VKTX?
By beta (market sensitivity over 5 years), ZyVersa Therapeutics, Inc.
(ZVSA) is the lower-risk stock at 0. 61β versus Viking Therapeutics, Inc. 's 1. 54β — meaning VKTX is approximately 154% more volatile than ZVSA relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 0% for Viking Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ZVSA or IMVT or PRAX or VKTX?
On earnings-per-share growth, the picture is similar: ZyVersa Therapeutics, Inc.
grew EPS 50. 7% year-over-year, compared to -215. 8% for Viking Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ZVSA or IMVT or PRAX or VKTX?
ZyVersa Therapeutics, Inc.
(ZVSA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Viking Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZVSA leads at 0. 0% versus 0. 0% for VKTX. At the gross margin level — before operating expenses — ZVSA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ZVSA or IMVT or PRAX or VKTX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ZVSA or IMVT or PRAX or VKTX better for a retirement portfolio?
For long-horizon retirement investors, ZyVersa Therapeutics, Inc.
(ZVSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61)). Viking Therapeutics, Inc. (VKTX) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ZVSA: -100. 0%, VKTX: +25. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ZVSA and IMVT and PRAX and VKTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.